Head-To-Head Review: PureTech Health (NASDAQ:PRTC) & GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics (NASDAQ:GLYC) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Earnings and Valuation

This table compares GlycoMimetics and PureTech Health”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GlycoMimetics	$10,000.00	1,729.35	-$36.90 million	N/A	N/A
PureTech Health	$3.33 million	137.33	-$65.70 million	N/A	N/A

GlycoMimetics has higher earnings, but lower revenue than PureTech Health.

Insider & Institutional Ownership

75.2% of GlycoMimetics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 8.7% of GlycoMimetics shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for GlycoMimetics and PureTech Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GlycoMimetics	0	3	0	0	2.00
PureTech Health	0	0	1	1	3.50

GlycoMimetics presently has a consensus price target of $8.00, suggesting a potential upside of 2,882.85%. PureTech Health has a consensus price target of $45.00, suggesting a potential upside of 135.58%. Given GlycoMimetics’ higher probable upside, equities analysts clearly believe GlycoMimetics is more favorable than PureTech Health.

Risk and Volatility

GlycoMimetics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500.

Profitability

This table compares GlycoMimetics and PureTech Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GlycoMimetics	N/A	-160.93%	-132.85%
PureTech Health	N/A	N/A	N/A

About GlycoMimetics

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.